These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16278491)

  • 1. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
    Basso AD; Kirschmeier P; Bishop WR
    J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
    J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
    Russo P; Loprevite M; Cesario A; Ardizzoni A
    Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors.
    Appels NM; Tung KO; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2006 Feb; 20(2):161-5. PubMed ID: 16032760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.
    Whyte DB; Kirschmeier P; Hockenberry TN; Nunez-Oliva I; James L; Catino JJ; Bishop WR; Pai JK
    J Biol Chem; 1997 May; 272(22):14459-64. PubMed ID: 9162087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].
    Geryk-Hall M; Yang Y; Hughes DP
    Mol Cancer Ther; 2010 May; 9(5):1111-9. PubMed ID: 20406948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using inhibitors of prenylation to block localization and transforming activity.
    Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
    Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
    Crul M; de Klerk GJ; Beijnen JH; Schellens JH
    Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
    Sousa SF; Fernandes PA; Ramos MJ
    Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein prenylation for cancer therapy.
    Berndt N; Hamilton AD; Sebti SM
    Nat Rev Cancer; 2011 Oct; 11(11):775-91. PubMed ID: 22020205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible inactivation of the transcriptional function of P53 protein by farnesylation.
    Couderc B; Penary M; Tohfe M; Pradines A; Casteignau A; Berg D; Favre G
    BMC Biotechnol; 2006 May; 6():26. PubMed ID: 16732889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitor as anticancer agent.
    Agrawal AG; Somani RR
    Mini Rev Med Chem; 2009 Jun; 9(6):638-52. PubMed ID: 19519490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.